MAIA Biotechnology (MAIA) announced that the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine, THIO, alone or before administration of checkpoint inhibitors, CPIs. The patent, titled “Mercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere,” was invented by MAIA’s Chief Scientific Officer Sergei M. Gryaznov, PhD and Scientific Advisory Board member Jerry W. Shay, PhD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAIA:
- MAIA Biotechnology’s Ateganosine Receives FDA Fast Track
- MAIA Biotechnology granted fast track designation for ateganosine
- MAIA Biotechnology Publishes Promising Preclinical Cancer Data
- MAIA Biotechnology announces publication of ateganosine prodrug data
- MAIA Biotechnology Begins Phase 2 Trial Expansion